Please login to the form below

Not currently logged in
Email:
Password:

Stem cell

This page shows the latest Stem cell news and features for those working in and with pharma, biotech and healthcare.

J&J expands Darzalex use with another first-line FDA approval

J&J expands Darzalex use with another first-line FDA approval

It is approved for newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).

Latest news

  • Bluebird Bio reveals further encouraging data for CALD gene therapy Bluebird Bio reveals further encouraging data for CALD gene therapy

    The only current treatment for the disease is stem cell transplant, but it carries a significant risk from the high-dose chemotherapy used to prepare patients for the procedure. ... Bluebird's treatment works by extracting patients' stem cells and

  • Vertex eyes type 1 diabetes cure with biotech acquisition Vertex eyes type 1 diabetes cure with biotech acquisition

    According to Vertex, the biotech is pioneering the use of stem cells as a potential cure for type 1 diabetes. ... Following the acquisition of Semma, Vertex is likely to find a rival in Novo Nordisk, which  last year said it has reached a milestone in

  • Bayer takes control of BlueRock stem cell joint venture Bayer takes control of BlueRock stem cell joint venture

    Deal values BlueRock at $1bn. Bayer is buying out private equity partner Versant Ventures and founders in its cell therapy joint venture BlueRock Therapeutics for $240m, three years after setting up ... The start-up intends to develop off-the-shelf

  • Bluebird puts €1.57m price on gene therapy Zynteglo Bluebird puts €1.57m price on gene therapy Zynteglo

    As the therapy is only currently licensed for use in beta thalassemia patients who have no matching stem cell donor, Obershain says this would make benchmarking its price against the cost ... of a stem cell transplant ($500, 000- $1m) inappropriate.

  • Setback for Takeda as Ninlaro flunks amyloidosis trial Setback for Takeda as Ninlaro flunks amyloidosis trial

    It’s not the first setback for Ninlaro. Takeda had been closing in on a maintenance indication for Ninlaro in post-stem cell transplant myeloma patients after reporting progression-free survival

More from news
Approximately 7 fully matching, plus 208 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Its only immediate competition will be donor stem cell transplants, which carry significant patient risks.

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Much of this pricing is based on direct comparisons with the costs of lifelong blood transfusions and haematopoietic stem cell (HSC) transplantation. ... won’t need the high-cost allogeneic haematopoietic stem cell transplantation which is currently

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The analysts predict the drug will be priced at around $550,

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Raju Prasad says Bluebird can offer a compelling cost-effectiveness case for its treatment in beta thalassemia and sickle cell cases versus conventional stem cell treatment. ... Conventional stem cell transplants cost anywhere between $500, 000 and $1m,

  • Reaching the new influencers Reaching the new influencers

    Right now, we’re living through healthcare’s age of accelerations - as evidenced by advances in everything from biotechnology and stem cell research to machine learning and the advent (and approvals)

More from intelligence
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory ... be a global leader in the

  • Porterhouse Medical promotes Emma Conran Porterhouse Medical promotes Emma Conran

    Conran has served in medical writing positions at Porterhouse Medical since 2014 and prior to that she was a translational stem cell biology lecturer at King’s College London.

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    successful track record as one of the leading CDMOs for complex cell and gene therapy products. ... Moreover, Dusan’s experience will strongly promote our dynamic innovative strategy behind apceth’s unique proprietary pipeline of genetically modified

  • Dr Jay Stout moves from Merck to SanBio Dr Jay Stout moves from Merck to SanBio

    In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development. ... He is perhaps the individual with the greatest experience in the world in manufacturing

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Spotlight interview: 15 minutes on medical and scientific writing

    A number of current therapeutic approaches – such as gene editing, gene therapy, and stem-cell therapy – were not in existence when many healthcare professionals (HCPs) underwent their training, so there is

  • Pegasus expands Pharma team with senior hires

    He has delivered brand and advertising campaigns for a range of clients including Roche, UK Stem Cell Foundation and Department of Health, as well as BBC Worldwide, Procter &Gamble and Amazon.

  • Highlights in haematologic malignancy from ASH 2018

    A reduced risk of relapse was also seen when CD19-directed CAR T-cell therapy was followed by a first-time stem cell transplant in children with ALL. ... stem cell transplant for higher risk patients and less aggressive treatments for others).

  • Solaris Health looks at the gene therapy revolution

    As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene therapy approved by the EMA (European Medicines ... 1. The ground-breaking treatment uses a virus to

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... Dr Ivan Wall is an expert in all things stem cell.

More from PMHub
Approximately 2 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics